WEBULL
News
ABCL
3.450
-0.29%
-0.010
Weekly Report: what happened at ABCL last week (1222-1226)?
Weekly Report · 1d ago
AbCellera: Losing Its Undeserved Premium
Seeking Alpha · 6d ago
Weekly Report: what happened at ABCL last week (1215-1219)?
Weekly Report · 12/22 09:08
Will AbCellera’s (ABCL) Bruker Patent Settlement and Royalties Shift Its Long-Term Revenue Narrative?
Simply Wall St · 12/20 15:29
AbCellera Biologics Inc. Files Initial Statement of Beneficial Ownership for Director Stephen Quake
Reuters · 12/19 19:36
AbCellera (ABCL) Valuation Check After Bruker Patent Settlement, New Royalty Stream and Legal Overhang Removal
Simply Wall St · 12/19 06:23
AbCellera Secures Global Settlement and Patent License Deal
TipRanks · 12/18 19:57
AbCellera settles patent litigation with Bruker over microfluidic device tech
Seeking Alpha · 12/18 14:57
AbCellera, Bruker Reach Settlement Resolving Patent Litigation
Dow Jones · 12/18 14:51
AbCellera to receive $36M upfront in patent litigation settlement with Bruker
TipRanks · 12/18 14:20
AbCellera Strikes Patent License Deal With Bruker; Bruker To Pay $36M As Future Royalty Payments On Sales Of Beacon Optofluidic Platform Globally
Benzinga · 12/18 14:09
ABCELLERA AND BRUKER REACH GLOBAL SETTLEMENT OF PATENT LITIGATION
Reuters · 12/18 14:05
ABCELLERA BIOLOGICS INC - BRUKER TO PAY ABCELLERA $36 MLN UPFRONT AND FUTURE ROYALTIES
Reuters · 12/18 14:05
AbCellera Settles Patent Dispute With Bruker for $36 Million Plus Royalties
Reuters · 12/18 14:01
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 12/16 14:19
Weekly Report: what happened at ABCL last week (1208-1212)?
Weekly Report · 12/15 09:09
AbCellera to Present at J.P. Morgan Healthcare Conference
Reuters · 12/08 21:05
Weekly Report: what happened at ABCL last week (1201-1205)?
Weekly Report · 12/08 09:09
Assessing AbCellera Biologics (ABCL) Valuation as It Shifts Toward Proprietary Clinical Assets and Phase 1 Trials
Simply Wall St · 12/06 05:23
Monday 12/1 Insider Buying Report: DASH, ABCL
NASDAQ · 12/01 15:36
More
Webull provides a variety of real-time ABCL stock news. You can receive the latest news about Abcellera Biologics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.